BMRN Voxzogo Hits Endpoint in Hypochondroplasia Phase 3

BioMarin (BMRN) reported September 9 that Voxzogo met its primary endpoint in hypochondroplasia, a form of short stature with no approved targeted treatment. Shares closed at $64.41.

In CANOPY-HCH-3, the registrational Phase 3 trial, children taking Voxzogo (vosoritide) improved annualized growth velocity by 2.33 cm/yr versus placebo (p<0.0001). They also showed significant gains in standing height and height Z-score, plus a smaller but real arm-span improvement (p=0.004). The study enrolled 80 children ages 3 to 17 and was published in NEJM Evidence alongside a presentation at ESPE 2026.

Voxzogo is a C-type natriuretic peptide (CNP) analog given by daily injection. CNP is a natural signal that restrains the growth plate, and extra CNP counteracts the overactive FGFR3 signaling that stunts bone growth in skeletal dysplasias. The drug has been approved for achondroplasia since 2021, giving BioMarin years of commercial and safety experience to build on.

Hypochondroplasia is a related but distinct condition caused by milder FGFR3 variants. Patients tend to have less severe short stature than in achondroplasia but often present with disproportionately short arms and legs, which is why the arm-span readout carries weight. Until now, no registrational study had ever been run in the indication, and BioMarin estimates about 14,000 eligible children across its global footprint.

The readout extends BioMarin’s first-mover lead in skeletal dysplasia and opens a second label for the franchise. It lands the same week BridgeBio reported results for oral infigratinib, an FGFR3 inhibitor that hit its Phase 3 endpoints in achondroplasia and is now filed with the FDA. Investors are weighing whether Voxzogo’s injectable format can hold share against a once-daily pill.

BioMarin is also building a longer-term record. A separate investigator-led study reported that Voxzogo’s growth gains in hypochondroplasia were sustained over three years, suggesting the effect is durable rather than a one-year blip. For a drug already on the market in achondroplasia, that record of real-world safety and durability defends against an oral challenger that is still finishing its own longer-term follow-up and has yet to win a first approval.

The catch is market size and the modality gap. Hypochondroplasia is a smaller market than achondroplasia, and the arm-span benefit, while real, was more modest than the growth effect. The company plans U.S. and EU submissions in the second half of 2026. Watch those filings, which set the timeline for this label expansion and for the franchise’s defense against BridgeBio’s oral infigratinib.

What It Means for the Trade

The readout is a franchise-extension win with clean evidentiary quality: a registrational Phase 3, published in NEJM Evidence, with a 2.33 cm/year annualized growth velocity gain (p<0.0001) in 80 children, plus standing height, height Z-score, and arm-span improvements. For the stock, the value is not the hypochondroplasia revenue in isolation — roughly 14,000 eligible children globally is a fraction of the achondroplasia population — but the cumulative label architecture: each approved skeletal dysplasia makes Voxzogo the default CNP-analog therapy across the FGFR3-spectrum, and each makes the injectable-versus-oral comparison happen in a market BioMarin defined. The three-year durability data from the investigator-led study is the quiet strategic asset here — durability is precisely the question an oral challenger’s shorter follow-up record can’t answer yet.

The competitive clock is the reason this readout matters more than its market size. BridgeBio’s infigratinib filed its achondroplasia NDA the same week this hypochondroplasia data landed, and BioMarin’s response is to widen its franchise footprint and bank real-world safety experience before any oral competitor launches. First-mover in hypochondroplasia also has defensive value: if infigratinib or another oral follows BioMarin into the indication, it will be chasing an entrenched incumbent with a published Phase 3 — the mirror image of the achondroplasia dynamic where Voxzogo is the incumbent being challenged. Dated catalysts from here: the H2 2026 U.S. and EU submissions, and the parallel under-5 achondroplasia sNDA, which together determine whether Voxzogo’s franchise growth continues compounding through 2027.

Mechanism and Competitive Context

The biology travels between the two skeletal dysplasias, which is why this trial was low-risk relative to a novel indication. Hypochondroplasia is milder FGFR3 gain-of-function — different variants, same overactive receptor, same suppressed chondrocyte proliferation in the growth plate. Voxzogo’s CNP analog counteracts the downstream growth suppression regardless of which FGFR3 variant drives it, so a growth-velocity win in achondroplasia was a strong prior for hypochondroplasia; the trial confirmed it with the arm-span endpoint (p=0.004) doing real work, since disproportionate limb shortening is the clinical hallmark patients and parents notice most in this condition. No registrational study had ever run in hypochondroplasia — BioMarin just set the evidentiary standard for the entire indication, which is a competitive position in itself.

The modality fight is the one structural vulnerability. A daily injection is the modality gap in achondroplasia and will be again in hypochondroplasia; an oral small molecule that hits the same FGFR3 biology without needles will win the convenience argument at every new diagnosis unless Voxzogo’s safety-and-durability record outweighs it. BioMarin’s best card is exactly that record — years of market exposure, sustained three-year growth data, and a franchise physicians already trust. The market will now price the race on whether incumbency and durability beat convenience in pediatric endocrinology prescribing.

Risks and What Could Go Wrong

1. H2 filing friction: any regulatory delay on the hypochondroplasia or under-5 submissions extends the window in which infigratinib’s approval can reset prescriber expectations in achondroplasia before Voxzogo’s new labels land.
2. The arm-span effect’s modesty matters commercially — if the visible disproportionality benefit is small, payers and parents may discount the therapy’s practical value in a milder disease.
3. Infigratinib expands into hypochondroplasia fast: an oral competitor with a Phase 3 in the sister indication converts BioMarin’s new market into a contested one quickly.
4. Franchise concentration: with the ENPP1 write-off behind it, BioMarin’s growth story leans harder on every Voxzogo label event — a single stumble now carries outsized equity weight.

Position read: a clean, published, registrational win with a dated filing path — the kind of catalyst that supports holding BMRN through the infigratinib fight. The watch item is H2 filing acceptance, not the data itself.

Source: BioMarin Voxzogo hypochondroplasia press release · ClinicalTrials.gov: CANOPY-HCH-3